SMARCB1 and rhabdoid tumor: For further experiments, we selected SAHA (suberoylanilide hydroxamic acid/vorinostat) because it is FDA-approved and has been shown to be an effective agent in Smarcb1-negative rhabdoid tumors in our previous studies56.